Detalhe da pesquisa
1.
MHC-E-Restricted CD8+ T Cells Target Hepatitis B Virus-Infected Human Hepatocytes.
J Immunol
; 204(8): 2169-2176, 2020 04 15.
Artigo
Inglês
| MEDLINE | ID: mdl-32161099
2.
Identification and Functional Characterization of a Novel Fc Gamma-Binding Glycoprotein in Rhesus Cytomegalovirus.
J Virol
; 93(4)2019 02 15.
Artigo
Inglês
| MEDLINE | ID: mdl-30487278
3.
Natural Killer Cell Evasion Is Essential for Infection by Rhesus Cytomegalovirus.
PLoS Pathog
; 12(8): e1005868, 2016 08.
Artigo
Inglês
| MEDLINE | ID: mdl-27580123
4.
Late gene expression-deficient cytomegalovirus vectors elicit conventional T cells that do not protect against SIV.
JCI Insight
; 8(6)2023 03 22.
Artigo
Inglês
| MEDLINE | ID: mdl-36749635
5.
Cytomegalovirus-vaccine-induced unconventional T cell priming and control of SIV replication is conserved between primate species.
Cell Host Microbe
; 30(9): 1207-1218.e7, 2022 09 14.
Artigo
Inglês
| MEDLINE | ID: mdl-35981532
6.
Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacy.
Science
; 372(6541)2021 04 30.
Artigo
Inglês
| MEDLINE | ID: mdl-33766941
7.
Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity.
Sci Transl Med
; 11(501)2019 07 17.
Artigo
Inglês
| MEDLINE | ID: mdl-31316006
8.
Cytomegalovirus vectors expressing Plasmodium knowlesi antigens induce immune responses that delay parasitemia upon sporozoite challenge.
PLoS One
; 14(1): e0210252, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-30673723
9.
A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge.
Sci Transl Med
; 11(501)2019 07 17.
Artigo
Inglês
| MEDLINE | ID: mdl-31316007